Jing Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jing Chen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Xifu Liu
Ministry of Education Key Laboratory of Molecular and Cellular Biology; Hebei Anti-Tumor Molecular Target Technology Innovation Center; Hebei Research Center of the Basic Discipline of Cell Biology; College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
3 shared publications Ni Meng
Ministry of Education Key Laboratory of Molecular and Cellular Biology; Hebei Anti-Tumor Molecular Target Technology Innovation Center; Hebei Research Center of the Basic Discipline of Cell Biology; College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
2 shared publicationsXueke Sun
Ministry of Education Key Laboratory of Molecular and Cellular Biology; Hebei Anti-Tumor Molecular Target Technology Innovation Center; Hebei Research Center of the Basic Discipline of Cell Biology; College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
2 shared publicationsA. Jain
1 shared publicationA. Skanderup
1 shared publicationA. Takano
1 shared publication
Latest Publications
- 25 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 179, 110036
Design, synthesis, and mechanistic study of novel isoflavone derivatives as mitochondrial complex I inhibitors for non-small cell lung cancer treatment
- 25 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 179, 110036
Design, synthesis, and mechanistic study of novel isoflavone derivatives as mitochondrial complex I inhibitors for non-small cell lung cancer treatment
- 25 October 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 167, 115719
A novel B7-H4/CD3/CD28 trispecific antibody with the SpyTag-SpyCatcher technology suppresses the growth of colorectal cancer
- 25 October 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 167, 115719
A novel B7-H4/CD3/CD28 trispecific antibody with the SpyTag-SpyCatcher technology suppresses the growth of colorectal cancer
- Open Access
- 1 December 2023
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 18, 7173-7181
Screening, Expression and Identification of Nanobody Against Monkeypox Virus A35R
Introduction: The monkeypox (Mpox) virus epidemic presents a significant risk to global public health security. A35R, a crucial constituent of EEV, plays a pivotal role in virus transmission, serves as a vital target for vaccine development, and has potential for serological detection. Currently, there is a dearth of research on nanobodies targeting A35R. The purpose of this study is to identify specific nanobodies target A35R, so as to provide new antibody candidates for Mpox vaccine development and diagnostic kit development. Methods: Three nanobodies specific to the monkeypox virus protein A35R were screened from a naïve phage display library. After four rounds of panning, positive phage clones were identified by enzyme-linked immunosorbent assay (ELISA). Further, the nanobody fusion protein was constructed in pNFCG1-IgG1-Fc vector and expressed in HEK293F cells and purified by affinity chromatography. The specificity and affinity of the nanobodies were identified by ELISA. The binding kinetics of the VHH antibody to A35R were assessed via employment of a bio-layer interferometry (BLI) apparatus, thereby determining the nanobodies affinity. Results: The three purified nanobodies showed specific high-affinity binding MPXV A35R, of them, VHH-1 had the best antigen binding affinity (EC50 = 0.010 ug/mL). In addition, VHH-1 on Protein A biosensor can bind Mpox virus A35R, with an affinity constant of 54 nM as determined in BLI assay. Conclusion: In sum, we has obtained three nanobody strains against Mpox virus A35R with significant affinity and specificity, therefore laying an essential foundation for further research as well as the applications of diagnostic and therapeutic tools of Mpox virus.
- 1 December 2023
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 18, 7173-7181
Open AccessScreening, Expression and Identification of Nanobody Against Monkeypox Virus A35R
Introduction: The monkeypox (Mpox) virus epidemic presents a significant risk to global public health security. A35R, a crucial constituent of EEV, plays a pivotal role in virus transmission, serves as a vital target for vaccine development, and has potential for serological detection. Currently, there is a dearth of research on nanobodies targeting A35R. The purpose of this study is to identify specific nanobodies target A35R, so as to provide new antibody candidates for Mpox vaccine development and diagnostic kit development. Methods: Three nanobodies specific to the monkeypox virus protein A35R were screened from a naïve phage display library. After four rounds of panning, positive phage clones were identified by enzyme-linked immunosorbent assay (ELISA). Further, the nanobody fusion protein was constructed in pNFCG1-IgG1-Fc vector and expressed in HEK293F cells and purified by affinity chromatography. The specificity and affinity of the nanobodies were identified by ELISA. The binding kinetics of the VHH antibody to A35R were assessed via employment of a bio-layer interferometry (BLI) apparatus, thereby determining the nanobodies affinity. Results: The three purified nanobodies showed specific high-affinity binding MPXV A35R, of them, VHH-1 had the best antigen binding affinity (EC50 = 0.010 ug/mL). In addition, VHH-1 on Protein A biosensor can bind Mpox virus A35R, with an affinity constant of 54 nM as determined in BLI assay. Conclusion: In sum, we has obtained three nanobody strains against Mpox virus A35R with significant affinity and specificity, therefore laying an essential foundation for further research as well as the applications of diagnostic and therapeutic tools of Mpox virus.
- 8 September 2022
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 17 (9) , S605
EP16.03-036 Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC
- 8 September 2022
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 17 (9) , S605
EP16.03-036 Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC
- 17 January 2019
- Published by Wiley in International Journal of Cancer
- Vol. 144 (8) , 2051-2062
A BAP31 intrabody induces gastric cancer cell death by inhibiting p27kip1 proteasome degradation
B‐cell receptor‐associated protein 31 (BAP31) is a ubiquitously expressed endoplasmic reticulum (ER) membrane protein that has been found to be overexpressed in gastric intestinal‐type adenocarcinoma. We first studied the relationship of BAP31 with 84 kinds of tumor‐associated antigens and found that BAP31 can specifically interact with and regulate the proteasome degradation of the cyclin kinase inhibitor p27kip1, which is one of the most frequently dysregulated tumor suppressor proteins in human cancers. Therefore, we screened antibodies against BAP31 from a human VH single‐domain antibody library and expressed the antibodies intracellularly. It was found that one of the intrabodies (VH‐D1) specifically inhibited p27kip1 proteasome degradation, possibly by blocking the combination of BAP31 with p27kip1. VH‐D1 displayed therapeutic effects, as it was able to reduce the growth of human gastric cancer (GC) cell xenografts in nude mice. This effect was due to inhibition of the proliferation and subsequent activation of caspase‐dependent apoptosis. Thus, BAP31 is a potential target for the suppression of GC via an intrabody‐based approach.
- 17 January 2019
- Published by Wiley in International Journal of Cancer
- Vol. 144 (8) , 2051-2062
A BAP31 intrabody induces gastric cancer cell death by inhibiting p27kip1 proteasome degradation
B‐cell receptor‐associated protein 31 (BAP31) is a ubiquitously expressed endoplasmic reticulum (ER) membrane protein that has been found to be overexpressed in gastric intestinal‐type adenocarcinoma. We first studied the relationship of BAP31 with 84 kinds of tumor‐associated antigens and found that BAP31 can specifically interact with and regulate the proteasome degradation of the cyclin kinase inhibitor p27kip1, which is one of the most frequently dysregulated tumor suppressor proteins in human cancers. Therefore, we screened antibodies against BAP31 from a human VH single‐domain antibody library and expressed the antibodies intracellularly. It was found that one of the intrabodies (VH‐D1) specifically inhibited p27kip1 proteasome degradation, possibly by blocking the combination of BAP31 with p27kip1. VH‐D1 displayed therapeutic effects, as it was able to reduce the growth of human gastric cancer (GC) cell xenografts in nude mice. This effect was due to inhibition of the proliferation and subsequent activation of caspase‐dependent apoptosis. Thus, BAP31 is a potential target for the suppression of GC via an intrabody‐based approach.